[go: up one dir, main page]

WO2024175393A1 - Composition de dentifrice - Google Patents

Composition de dentifrice Download PDF

Info

Publication number
WO2024175393A1
WO2024175393A1 PCT/EP2024/053462 EP2024053462W WO2024175393A1 WO 2024175393 A1 WO2024175393 A1 WO 2024175393A1 EP 2024053462 W EP2024053462 W EP 2024053462W WO 2024175393 A1 WO2024175393 A1 WO 2024175393A1
Authority
WO
WIPO (PCT)
Prior art keywords
percent
composition
calcium
composition according
toothpaste composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2024/053462
Other languages
English (en)
Inventor
Alison Katharine Green
Robert Edward Marriott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Original Assignee
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Global IP Ltd, Unilever IP Holdings BV, Conopco Inc filed Critical Unilever Global IP Ltd
Priority to CN202480013999.5A priority Critical patent/CN120813337A/zh
Publication of WO2024175393A1 publication Critical patent/WO2024175393A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde

Definitions

  • the present invention is concerned with oral care compositions having a gum heath benefit.
  • the oral epithelial barrier of the gum comprises underlying connective tissue and a stratified keratinized epithelium with a basement membrane.
  • the oral epithelial barrier provides the first line of defence against pathogens, exogenous substances and mechanical stress chronic infection. Disruption of the gingival epithelial barrier, and the subsequent penetration of exogenous pathogens can trigger an inflammatory response leading to gum infection and receding of the gums.
  • Chlorhexidine may be used in oral care compositions to exert beneficial physiological effects, such as prevention or amelioration of gingivitis or periodontitis, prevention and treatment of dental caries, periodontal disease, and other diseases of the oral cavity.
  • EP2100590 and EP185971 discloses oral care compositions comprising chlorohexidine and alkyl glucoside surfactants.
  • the present invention relates to oral care compositions that enhance the effectiveness of chlorhexidine and enhance the gum barrier.
  • the present invention relates to atoothpaste composition
  • atoothpaste composition comprising: i) chlorohexidine and/or salt thereof ii) a vitamin B3 compound at a weight ratio of i) to ii) of 1:30 to 1 :2.
  • the invention further relates to a composition as described above for use in a method to maintain and/or enhance the gum barrier.
  • teethpaste composition refers to a composition that is delivered to the oral surfaces.
  • the composition may be a product which, during the normal course of usage, is not for the purpose of systemic administration or intentionally swallowed but is rather retained in the oral cavity for a time sufficient to contact substantially all of the dental surfaces and/or oral tissues for the purposes of oral activity.
  • Dentifrice compositions according to the invention comprise chlorhexidine or chlorhexidine salt. It is preferable if the chlorhexidine salt is chlorhexidine gluconate, chlorhexidine digluconate or mixtures thereof. More preferably the chlorhexidine salt is chlorohexidine digluconate.
  • the chlorhexidine salt preferably present from 0.05 to 1 wt% of the total composition, more preferably from 0.07wt% to 0.7 wt%. most preferably from 0.1 to 0.4 wt%.
  • Compositions of the invention comprise a Vitamin B3 compound.
  • the vitamin B3 compound maybe nicacin, nicotinic acid or niacinamide, preferably niacinamide.
  • Niacinamide is preferably present at 0.01 wt% to 5wt%, more preferably 0.5 wt% to 3.5 wt% of the total composition by weight of the composition.
  • the weight ratio of i) chlorohexidine and/or salt thereof to ii) a vitamin B3 compound is from 1 :25 to 1 :8. more preferably the weight ratio of i) chlorohexidine and/or salt thereof to ii) a vitamin B3 compound is greater than 1 :12.
  • composition of the invention is used to clean the surfaces of the oral cavity.
  • the composition of the invention in the form of a toothpaste.
  • teethpaste denotes an oral composition which is used to clean the surfaces of the oral cavity.
  • Such a composition is not intentionally swallowed for purposes of systemic administration of therapeutic agents, but is applied to the oral cavity, used to treat the oral cavity and then expectorated.
  • a cleaning implement such as a toothbrush, usually by applying it to the bristles of the toothbrush and then brushing the accessible surfaces of the oral cavity.
  • the dentifrice/toothpaste is in the form of an extrudable semi-solid such as a cream, paste or gel (or mixture thereof).
  • composition according to the invention will generally contain further ingredients to enhance performance and/or consumer acceptability, in addition to the ingredients specified above.
  • Compositions according to the invention preferably comprise particulate abrasive materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, calcium pyrophosphates, hydroxyapatites, trimetaphosphates, insoluble hexametaphosphates and so on, including agglomerated particulate abrasive materials, usually in amounts between 3 and 60% by weight of the oral care composition.
  • particulate abrasive materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, calcium pyrophosphates, hydroxyapatites, trimetaphosphates, insoluble hexametaphosphates and so on, including agglomerated particulate abrasive materials, usually in amounts between 3 and 60% by weight of the oral care composition.
  • the composition comprises a silica based abrasive.
  • the preferred abrasive silicas used in the present invention is a silica with a low refractive index. It may be used as the sole abrasive silica, or in conjunction with a low level of other abrasive silicas, e.g. those according to EP 236070.
  • the low refractive index silicas, used as abrasives in the present invention are preferably silicas with an apparent refractive index (R.l.) in the range of 1.41 - 1.47, preferably 1.435 - 1.445, preferably having a weight mean particle size of between 5 and 15 mm, a BET (nitrogen) surface area of between 10 and 100 m 2 /g and an oil absorption of about 70 - 150 cm 3 /100 g, but abrasive silicas with a lower apparent refractive index may also be used.
  • suitable low refractive index abrasive silicas e.g. having an R. I .
  • silicas of between 1.435 and 1 .445) are Tixosil 63 and 73 ex Rhone Poulenc; Sident 10 ex Degussa; Zeodent 113 ex Zeofinn; Zeodent 124 ex Evonik, Sorbosil AC 77 ex PQ Corporation (having an R.l. of approximately 1 .440).
  • the amount of these silicas in the composition generally ranges from 5-60% by weight, usually 5-20% by weight.
  • Natural calcium carbonate abrasive is typically a finely ground limestone which may optionally be refined or partially refined to remove impurities.
  • the material preferably has an average particle size of less than 10 microns, e.g., 3-7 microns, e.g., about 5.5 microns.
  • a small particle silica may have an average particle size (D50) of 2.5 -4.5 microns.
  • natural calcium carbonate may contain a high proportion of relatively large particles of not carefully controlled, which may unacceptably increase the abrasivity, preferably no more than 0.01 wt%, preferably no more than 0.004 percent by weight of particles would not pass through a 325 mesh.
  • the material has strong crystal structure, and is thus much harder and more abrasive than precipitated calcium carbonate.
  • the tapped density for the natural calcium carbonate is for example between 1 and 1.5 g/cc, e.g., about 1.2 for example about 1.19 g/cc.
  • polymorphs of natural calcium carbonate e.g., calcite, aragonite and vaterite, calcite being preferred for purposes of this invention.
  • Precipitated calcium carbonate has a different crystal structure from natural calcium carbonate. It is generally more friable and more porous, thus having lower abrasivity and higher water absorption.
  • the particles are small, e.g., having an average particle size of 1-5 microns, and e.g., no more than 0.1 percent, preferably no more than 0.05 percent by weight of particles which would not pass through a 325 mesh.
  • the particles may for example have a D50 of 3-6 microns, for example 3.8-4.9, e.g., about 4.3; a D50 of 1-4 microns, e.g., 2.2-2.6 microns, e.g., about 2.4 microns, and a D10 of 1-2 microns, e.g., 1.2-1.4, e.g., about 1.3 microns.
  • the particles have relatively high water absorption, e.g., at least 25 g/100 g, e.g., 30-70 g/100 g.
  • additional calcium-containing abrasives for example calcium phosphate abrasive, e.g., tricalcium phosphate, hydroxyapatite or dicalcium phosphate dihydrate or calcium pyrophosphate, and/or silica abrasives, sodium metaphosphate, potassium metaphosphate, aluminum silicate, calcined alumina, or other siliceous materials, or combinations thereof are used.
  • the composition particularly if a toothpaste preferably comprises an inorganic or a natural or synthetic thickener or gelling agent in proportions of about 0.10 to about 15% by weight depending on the material chosen.
  • thickeners in the dentifrice compositions of the present invention form an extrudable, shape-retaining product which can be squeezed from a tube onto a toothbrush and will not fall between the bristles of the brush but rather, will substantially maintain its shape thereon.
  • Suitable thickeners or gelling agents useful in the practice of the present invention include inorganic thickening silicas such as amorphous silicas available from Huber Corporation under the trade designation Zeodent 165, Irish moss, iota-carrageenan, gum tragacanth, and polyvinylpyrrolidone.
  • binders and thickeners can be present and include as sodium carboxymethylcellulose, hydroxyethyl cellulose (Natrosol®), xanthan gum, gum arabic etc. as well as synthetic polymers such as polyacrylates and carboxyvinyl polymers such as Carbopol®.
  • compositions according to the invention may comprise a polymeric deposition aid.
  • the composition comprises acid anhydride polymers, particularly preferred are co-polymers of maleic anhydride with methyl vinylether, in which the anhydride moiety may be in a partially or fully hydrolysed or alcoholysed form.
  • Preferred copolymers include Gantrez(R) polymers such as:
  • Gantrez S-95 molecular weight 216,000; free acid
  • Gantrez S-96 molecular weight 700,000; free acid
  • Gantrez S-97 molecular weight 1 ,500,000; free acid
  • Gantrez MS-955 molecular weight 1,060,000; calcium/sodium salt.
  • Particularly preferred co-polymers of maleic acid and methyl vinylether have a molecular weight of 1 ,000,000 or greater and an especially preferred material is Gantrez S-97.
  • compositions according to the invention may comprise a tooth whitening agent.
  • the whitening agent preferably comprises a green and/or a blue pigment.
  • a pigment is generally understood to be a shade/material which is insoluble in the relevant medium, at the relevant temperature. This is in contrast to dyes which are soluble.
  • the "relevant medium” is human saliva, the liquid medium in which the composition is used, at the temperature of the oral cavity during brushing of the teeth, i.e. up to 37 Degrees C. As a reasonable approximation, the relevant medium may be considered to be water and the relevant temperature to be 25 Degrees C.
  • the blue pigment is Pigment Blue 15, more preferably Pigment Blue 15:1 , 15:2, 15:3, 15:4, 15:5 or 15:6, most preferably 15:1.
  • a preferred pigment is blue pigment is Phthalocyanine Blue Pigment, Cl No. 74160, blue covarine.
  • the preferred Green pigment is Phthalocyanine Green, preferably Phthalocyanine Green CI- 74260.
  • the total level of pigment in the composition is from 0.01 wt% to 3 wt, more preferably from 0.02 to 2 wt%.
  • composition is a toothpaste it may be a dual phase paste, with the whitening pigments present in one phase.
  • Compositions according to the invention may comprise water-soluble or sparingly water-soluble sources of metal salts.
  • zinc ions such as zinc chloride, zinc acetate, zinc gluconate, zinc sulphate, zinc fluoride, zinc citrate, zinc lactate, zinc oxide, zinc monoglycerolate, zinc tartrate, zinc pyrophosphate and zinc maleate; also preferred are stannous ions such as stannous fluoride and stannous chloride.
  • compositions according to the invention may comprise oral care enzyme systems such as hydrogen peroxide producing enzyme systems (e.g. the oxidoreductase enzyme glucose oxidase), amyloglucosidase, dextranase and/or mutanase, (optionally in the presence of zinc ion providing compounds and/or 8- hydroxyquinoline derivatives), lactoperoxidase, lactoferrin, lysozyme and mixtures thereof.
  • hydrogen peroxide producing enzyme systems e.g. the oxidoreductase enzyme glucose oxidase
  • amyloglucosidase e.g. the oxidoreductase enzyme glucose oxidase
  • dextranase and/or mutanase e.g. the oxidoreductase enzyme glucose oxidase
  • mutanase e.g. the mutanase
  • lactoperoxidase e.g. the
  • Compositions of the invention may comprise fluoride sources such as sodium fluoride, stannous fluoride, sodium monofluorophosphate, zinc ammonium fluoride, tin ammonium fluoride, calcium fluoride, cobalt ammonium fluoride and mixtures thereof.
  • Fluoride ion sources may be added to the compositions at a level of about 0.001 wt. percent to about 10 wt. percent, e.g., from about 0.003 wt. percent to about 5 wt. percent, 0.01 wt. percent to about 1 wt., or about 0.05 wt. percent.
  • the stannous fluoride is present in an amount of 0.1 wt. percent to 2 wt.
  • Fluoride ion sources may be added to the compositions at a level of about 0.001 wt. percent to about 10 wt. percent, e.g., from about 0.003 wt. percent to about 5 wt. percent, 0.01 wt. percent to about 1 wt., or about 0.05 wt. percent.
  • weights of fluoride salts to provide the appropriate level of fluoride ion will obviously vary based on the weight of the counter ion in the salt, and one of skill in the art may readily determine such amounts.
  • the fluoride source is a fluoride salt present in an amount of 0.1 wt. percent to 2 wt. percent (0.1 wt percent -0.6 wt. percent) of the total composition weight (e.g., sodium fluoride (e.g., about 0.32 wt. percent).
  • Some embodiments of the invention are free from fluoride sources, that is the composition comprises less than 0.01 wt% of a fluoride source.
  • a preferred class of oral care active for inclusion in the compositions of the invention includes agents for the remineralisation of teeth.
  • remineralisation in the context of the present invention means the in situ generation of hydroxyapatite on teeth.
  • a specific example of a suitable agent for the remineralisation of teeth is a mixture of a calcium source and a phosphate source which, when delivered to the teeth results in the in situ generation of hydroxyapatite on teeth.
  • remineralising calcium sources include, for example, calcium phosphate, calcium gluconate, calcium oxide, calcium lactate, calcium glycerophosphate, calcium carbonate, calcium hydroxide, calcium sulphate, calcium carboxymethyl cellulose, calcium alginate, calcium salts of citric acid, calcium silicate and mixtures thereof.
  • the remineralising calcium source is calcium silicate.
  • the amount of remineralising calcium source(s) (e.g. calcium silicate) in the composition of the invention typically ranges from 1 to 30%, preferably from 5 to 20% by total weight remineralising calcium source based on the total weight of the oral care composition.
  • remineralising phosphate sources include, for example, monosodium dihydrogen phosphate, disodium hydrogen phosphate, sodium pyrophosphate, tetrasodium pyrophosphate, sodium tripolyphosphate, sodium hexametaphosphate, potassium dihydrogenphosphate, trisodium phosphate, tripotassium phosphate and mixtures thereof.
  • the remineralising phosphate source is a mixture of trisodium phosphate and sodium dihydrogen phosphate.
  • the amount of remineralising phosphate source(s) (e.g. trisodium phosphate and sodium dihydrogen phosphate) in the composition of this invention typically ranges from 2 to 15%, preferably from 4 to 10% by total weight remineralising phosphate source based on the total weight of the oral care composition.
  • the oral care compositions comprise an effective amount of one or more antibacterial agents, for example comprising an antibacterial agent selected from halogenated diphenyl ether (e.g. triclosan), triclosan monophosphate, herbal extracts and essential oils (e.g., rosemary extract, tea extract, magnolia extract, thymol, menthol, eucalyptol, geraniol, carvacrol, citral, hinokitol, magnolol, ursolic acid, ursic acid, catechol, methyl salicylate, epigallocatechin gallate, epigallocatechin, gallic acid, miswak extract, sea-buckthorn extract), bisguanide antiseptics (e.g.alexidine or octenidine), quaternary ammonium compounds (e.g., cetylpyridinium chloride (CPC), CPC-claybenzalkonium chloride, tetradecylpyridinium chloride (TPC), N
  • One or more additional antibacterial or preservative agents may optionally be present in the composition in a total amount of from about 0.01 wt. percent to about 0.5 wt. percent, optionally about 0.05 wt. percent to about 0.1 wt. percent or about 0.3 percent, by total weight of the composition.
  • the oral care compositions also comprise at least one flavorant, useful for example to enhance taste of the composition.
  • Any orally acceptable natural or synthetic flavorant can be used, including without limitation essential oils and various flavoring aldehydes, esters, alcohols, and similar materials, tea flavors, vanillin, sage, marjoram, parsley oil, spearmint oil, cinnamon oil, oil of Wintergreen, peppermint oil, clove oil, bay oil, anise oil, eucalyptus oil, citrus oils, fruit oils, sassafras and essences including those derived from lemon, orange, lime, grapefruit, apricot, banana, grape, apple, strawberry, cherry, pineapple, etc., bean-and nut-derived flavors such as coffee, cocoa, cola, peanut, almond, etc., adsorbed and encapsulated flavorants and the like.
  • ingredients that provide fragrance and/or other sensory effect in the mouth, including cooling or warming effects.
  • Such ingredients illustratively include menthol, carvone, menthyl acetate, menthyl lactate, camphor, eucalyptus oil, eucalyptol, anethole, eugenol, cassia, oxanone, a- irisone, , thymol, linalool, benzaldehyde, cinnamaldehyde, N-ethyl-p-menthan-3-carboxamine,
  • One or more flavorants are optionally present in a total amount of from about 0.01 wt. percent to about 5 wt. percent, for example, from about 0.03 wt. percent to about 2.5 wt. percent, optionally about 0.05 wt. percent to about 1.5 wt. percent, further optionally about 0.1 wt. percent to about 0.3 wt. percent and in some embodiments in various embodiments from about 0.01 wt. percent to about 1 wt. percent, from about 0.05 to about 2 percent, from about 0.1 percent to about 2.5 percent, and from about
  • the oral care compositions comprise at least one sweetener, useful for example to enhance taste of the composition.
  • Sweetening agents among those useful herein include dextrose, polydextrose, sucrose, maltose, dextrin, dried invert sugar, mannose, xylose, ribose, fructose, levulose, galactose, corn syrup, partially hydrolyzed starch, hydrogenated starch hydrolysate, ethanol, sorbitol, mannitol, xylitol, maltitol, isomalt, aspartame, neotame, saccharin and salts thereof (e.g. sodium saccharin), sucralose, dipeptide-based intense sweeteners, cyclamates, dihydrochalcones.
  • sweetening agents include dextrose, polydextrose, sucrose, maltose, dextrin, dried invert sugar, mannose, xylose, ribose, fructo
  • One or more sweeteners are optionally present in a total amount depending strongly on the particular sweetener (s) selected, but typically 0.005 wt. percent to 5 wt. percent, by total weight of the composition, optionally 0.005 wt. percent to 0.2 wt. percent, further optionally 0.05 wt. percent to 0.1 wt. percent by total weight of the composition.
  • the oral care compositions further comprise an agent that interferes with or prevents bacterial attachment, e.g., ethyl lauroyl arginiate (ELA), solbrol or chitosan, as well as plaque dispersing agents such as enzymes (papain, glucoamylase, etc.).
  • an agent that interferes with or prevents bacterial attachment e.g., ethyl lauroyl arginiate (ELA), solbrol or chitosan
  • EVA ethyl lauroyl arginiate
  • solbrol solbrol
  • chitosan e.g., chitosan
  • plaque dispersing agents such as enzymes (papain, glucoamylase, etc.).
  • composition according the invention will comprise further ingredients which are common in the art, such as: antimicrobial agents, e.g. chlorhexidine, sanguinarine extract, metronidazole, quaternary ammonium compounds, such as cetylpyridinium chloride; cetylpyridium chloride clay complex bis- guanides, such as chlorhexidine digluconate, hexetidine, octenidine, alexidine; and halogenated bisphenolic compounds, such as 2,2' methylenebis-(4-chloro-6-bromophenol); anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, indomethacin etc.; anti-caries agents such as sodium- and stannous fluoride, aminefluorides, sodium monofluorophosphate, sodium trimeta phosphate and casein; plaque buffers such as urea, calcium lactate, calcium glycerophosphate and strontium polyacrylates; vitamins such as Vitamins A
  • Humectants such as glycerol, sorbitol, propyleneglycol, xylitol, lactitol etc.;
  • SkinEthic® was incubated with human gingival epithelium (HGE) at 37°C, 5% CO2 overnight with SkinEthic maintenance medium ( hydrocortisone-free ).
  • HGE human gingival epithelium
  • the upper surface of the HGE tissues was treated with toothpaste slurry or endotoxin-free water (negative contraband incubated at room temperature for 4 minutes, then the upper surface of the culyure was wahed to remove the test materials. All treatments were repeated to provide triplicates. After washing the HE wasincubated at 37 0 C, 5% CO 2 2 for 24 hours.
  • Keratin 13 The HGE tissues were harvested and RNA extracted. qPCR was perfomed on RNA extracted from the tissues (keratin 13). Table 2 *Gene expression for Keratin 13 (or cytokeratin 13). Keratin 12is protein that in humans is encoded by the KRT13 gene and found in the gum barrier. Keratin 13 is a key structural protein found in the oral epithelia and is a known marker of keratinocyte differentiation.
  • a higher relative gene expression of keratin 13 relates to improved differentiation and enhanced gum barrier, thus the Examples of the invention have improved gum barrier properties.
  • Table 3 is a further Example of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition de soin buccal comprenant i) de la chlorohexidine et/ou un sel de celle-ci, ii) un composé de vitamine B3 selon un rapport pondéral d'i) à ii) de 1:30 à 1:2.
PCT/EP2024/053462 2023-02-22 2024-02-12 Composition de dentifrice Ceased WO2024175393A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202480013999.5A CN120813337A (zh) 2023-02-22 2024-02-12 牙膏组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23157941.8 2023-02-22
EP23157941 2023-02-22

Publications (1)

Publication Number Publication Date
WO2024175393A1 true WO2024175393A1 (fr) 2024-08-29

Family

ID=85328681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/053462 Ceased WO2024175393A1 (fr) 2023-02-22 2024-02-12 Composition de dentifrice

Country Status (2)

Country Link
CN (1) CN120813337A (fr)
WO (1) WO2024175393A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185971A1 (fr) 1984-12-10 1986-07-02 Henkel Kommanditgesellschaft auf Aktien Application d'alkylglycosides comme potentiateurs dans les agents antiseptiques ainsi que les agents de désinfection et nettoyage avec une activité bactéricide élevée
EP0236070A2 (fr) 1986-02-28 1987-09-09 Unilever Plc Silices
US20060134020A1 (en) * 2004-12-21 2006-06-22 Robinson Richard S Anti-caries oral care composition with a chelating agent
EP2100590A1 (fr) 2006-11-14 2009-09-16 Sunstar Inc. Composition orale contenant de la cellulose cristalline traitée en surface avec une substance soluble dans l'eau
DE102012211347A1 (de) * 2012-06-29 2014-01-02 Henkel Ag & Co. Kgaa Lactoperoxidase-aktivierendes Mund- und Zahnpflege- und -reinigungsmittel
CN103735570A (zh) * 2013-12-13 2014-04-23 中国人民解放军第四军医大学 一种预防口腔真菌感染的口腔护理液

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185971A1 (fr) 1984-12-10 1986-07-02 Henkel Kommanditgesellschaft auf Aktien Application d'alkylglycosides comme potentiateurs dans les agents antiseptiques ainsi que les agents de désinfection et nettoyage avec une activité bactéricide élevée
EP0236070A2 (fr) 1986-02-28 1987-09-09 Unilever Plc Silices
US20060134020A1 (en) * 2004-12-21 2006-06-22 Robinson Richard S Anti-caries oral care composition with a chelating agent
EP2100590A1 (fr) 2006-11-14 2009-09-16 Sunstar Inc. Composition orale contenant de la cellulose cristalline traitée en surface avec une substance soluble dans l'eau
DE102012211347A1 (de) * 2012-06-29 2014-01-02 Henkel Ag & Co. Kgaa Lactoperoxidase-aktivierendes Mund- und Zahnpflege- und -reinigungsmittel
CN103735570A (zh) * 2013-12-13 2014-04-23 中国人民解放军第四军医大学 一种预防口腔真菌感染的口腔护理液

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GNPD [online] MINTEL; 14 August 2013 (2013-08-14), ANONYMOUS: "Mouthwash", XP093065720, retrieved from https://www.gnpd.com/sinatra/recordpage/2143549/ Database accession no. 2143549 *

Also Published As

Publication number Publication date
CN120813337A (zh) 2025-10-17

Similar Documents

Publication Publication Date Title
US11612553B2 (en) Oral care product and methods of use and manufacture thereof
US9717929B2 (en) Dentifrice compositions containing calcium silicate and a basic amino acid
RU2744785C2 (ru) Композиции для ухода за полостью рта и способы их применения
EP3883538B1 (fr) Réduction des bactéries pathogènes grâce à l'arginine
AU2017414704B2 (en) Oral care compositions and methods of use
EP2793809B1 (fr) Compositions de soin orales
US20180333349A1 (en) Oral Care Compositions and Methods of Use
EP2793811B1 (fr) Compositions de soins buccaux
EP3883530B1 (fr) Procédés d'inhibition du recrutement des neutrophiles au niveau du sulcus gingival
WO2024175393A1 (fr) Composition de dentifrice
AU2019416034B2 (en) Methods of inducing sIgA and mucin 5B in the oral cavity
WO2025233091A1 (fr) Composition de soin buccal comprenant de l'arginine ou des sels de celle-ci et de l'asparagine ou des sels de celle-ci
WO2024231022A1 (fr) Composition de soin buccal à goût amélioré comprenant du bicarbonate de sodium
EP4420737A1 (fr) Composition de soin buccal
WO2025153291A1 (fr) Composition de soin buccal
WO2025190611A1 (fr) Composition de soin buccal contenant du zinc à faible astringence
WO2025190613A1 (fr) Composition de soin buccal ayant un dépôt de calcium amélioré
WO2025153301A1 (fr) Composition de soin buccal
EP4483861A1 (fr) Composition de soin buccal comprenant un alkylpolyglucoside
WO2025176405A1 (fr) Composition de soin buccal
WO2025180682A1 (fr) Composition de soin buccal
EP4420736A1 (fr) Composition de soin buccal
US20210059914A1 (en) Zinc Phosphate Containing Compositions
WO2024149491A1 (fr) Composition de soins buccodentaires
EP4420735A1 (fr) Composition de soin buccal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24704446

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 202480013999.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 202527080749

Country of ref document: IN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025017605

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 202527080749

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2024704446

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 202480013999.5

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2024704446

Country of ref document: EP

Effective date: 20250922

ENP Entry into the national phase

Ref document number: 2024704446

Country of ref document: EP

Effective date: 20250922